STS Intermacs 2025年度报告:聚焦老年患者结局
STS Intermacs第16次年度报告纳入2015至2024年植入的28,029例连续流左心室辅助装置(CF LVAD)患者,全磁悬浮CF LVAD的1年、5年、7年生存率分别为85.9%、60.2%、51.8%。≥65岁患者1年生存率80.6%、5年生存率51.1%,生活质量与不良事件结局良好,但全国耐久LVAD植入量停滞。
要点
- 全磁悬浮CF LVAD的1年生存率85.9%、5年60.2%、7年51.8%
- ≥65岁患者1年生存率80.6%、5年51.1%,生活质量与不良事件结局良好
- 全国耐久LVAD植入量停滞,需修订患者选择标准以缩小实施差距
核心结论
- 全磁悬浮CF LVAD生存结局优异且不良事件发生率低,老年患者同样获益,但全国植入量停滞。
研究设计与样本
- STS Intermacs第16次年度报告,纳入2015至2024年植入的28,029例连续流左心室辅助装置患者。
主要发现
- 全磁悬浮CF LVAD的1年生存率85.9%、5年生存率60.2%、7年生存率51.8%。
- 5年免于胃肠道出血、装置故障、卒中的比例分别为73.5%、81.8%、87.1%。
- ≥65岁患者1年生存率80.6%、5年生存率51.1%,生活质量与不良事件结局良好。
- 全国耐久LVAD植入量停滞。
临床怎么用
- 对符合移植条件的老年患者,心脏移植列表与耐久LVAD支持之间需个体化、基于价值的治疗决策。
- 七十余岁患者5年生存率可超过50%,应修订患者选择标准并缩小实施差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 16th Annual Report from the Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) includes 28,029 continuous-flow left ventricular assist devices (CF LVADs) implanted from 2015 to 2024. Survival remains excellent with the fully magnetically levitated CF LVAD (1-year survival: 85.9%, 5-year survival: 60.2%, 7-year survival: 51.8%). Patients also experience a low incidence of adverse events, including freedom from gastrointestinal bleeding (73.5%), device malfunction (81.8%), and stroke (87.1%) at 5 years, reinforcing the effectiveness of contemporary device platforms. However, despite these advancements, national durable LVAD implant volumes have remained stagnant. A focus on the subgroup of patients aged ≥65 years demonstrates excellent outcomes with respect to survival (1-year survival: 80.6%, 5-year survival: 51.1%), quality of life measures, and adverse events. Survival outcomes in this cohort are robust across a wide spectrum of clinical scenarios, including variation in acuity of illness, temporary mechanical circulatory support use, and psychosocial risk factors, historically associated with worse outcomes. Several clinical inferences may be drawn from these data. First, the increasingly elusive clinical equipoise between heart transplant listing vs a strategy of durable LVAD support merits an individualized and value-based approach to therapy in transplant-eligible older adults. Second, the prospect of 5-year survival exceeding 50%-even in septuagenarians-is a call to action to revise patient eligibility criteria, close the implementation gap, and realize the full potential of this life-saving therapy.
引用
- Nayak A, Cascino TM, DeFilippis EM, et al. The Society of Thoracic Surgeons Intermacs 2025 Annual Report: Focus on Outcomes in Older Adults. Ann Thorac Surg. 2025. PMID: 41177301. doi:10.1016/j.athoracsur.2025.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。